JUNO
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
Estimated
Arlocabtagene Autoleucel
Multiple Myeloma
T-minus 358 days
~ Jun 30, 2027
ClinicalTrials.gov
verified 15h ago
Countdown card →